Abaloparatide
Brand Names: Tymlos
Methodology & AI Transparency ⓘ
Abaloparatide Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage tymlos: is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy.
- 2 Real-world patient consensus: Zero-PHI community consensus: 89% favorable across 4 logged regimens (Tymlos).
- 3 Typical cash cost range: Dispensing cost comparison spans $59.94 mail/discount cash up to $146.85 uninsured retail (federal NADAC $1.2700).
- 4 Top reported side effects / signs: Most commonly reported Abaloparatide tolerability events: nausea (9.9%), headache (8.5%), dizziness (7.8%).
Ask our AI Specialists anything about Abaloparatide
Abaloparatide Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage tymlos: is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1.1 ) Treatment to increase bone density in men with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy.
12.1 Mechanism of Action Abaloparatide is a PTHrP(1-34) analog which acts as an agonist at the PTH1 receptor (PTH1R). This results in activation of the cAMP signaling pathway in target cells. Once-daily administration of abaloparatide stimulates new bone formation on trabecular and cortical bone surfaces by stimulation of osteoblastic activity. In rats and monkeys, abaloparatide had an anabolic effect on bone, demonstrated by increases in BMD and bone mineral content (BMC) that correlated with increases in bone strength at vertebral and/or nonvertebral sites .
With Steady-state plasma equilibrium reached over 3–10 hour t½ intervals for Abaloparatide residence kinetics and Complete (~100%) parenteral systemic delivery for Abaloparatide (3.12 mg/1.56mL Injection, Solution) bioavailability, Abaloparatide undergoes predominantly hepatic biotransformation with renal elimination of polar abaloparatide conjugates and establishes therapeutic activity over rapid intravascular/parenteral onset within 15–45 minutes after abaloparatide administration.
Standard adult regimens span 3.12 mg/1.56mL Injection, Solution, 80 mcg. Prescribers screen specifically against 4 contraindications tymlos is contraindicated in patients with a history of severe hypersensitivity to abaloparatide or any of the inactive ingredients of tymlos.; reactions have included anaphylaxis, angioedema, dyspnea, and urticaria .; severe hypersensitivity to abaloparatide or any of the inactive ingredients of tymlos., while community micro-logs most frequently note nausea (9.9% of reports), headache (8.5% of reports), dizziness (7.8% of reports).
Reconcile eGFR-adjusted medications before escalating Abaloparatide in polypharmacy regimens.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Abaloparatide dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS TYMLOS is contraindicated in patients with a history of severe hypersensitivity to abaloparatide or any of the inactive ingredients of TYMLOS.
- Reactions have included anaphylaxis, angioedema, dyspnea, and urticaria .
- Severe hypersensitivity to abaloparatide or any of the inactive ingredients of TYMLOS.
Logged Side-Effect Incidence (4 Reports)
Abaloparatide Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Abaloparatide)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Effects of abaloparatide on acetabular bone mineral density and proximal femur E In conclusion, abaloparatide improved measured properties in men with osteoporosis on acetabular and femoral sides of the hip joint, increasing acetabular BMD and improving femur strength. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry • 2026-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41812602 ↗ |
| Can This Approach Help? Inside the Latest Research on Effects of abaloparatide on hip geometry and biomechanical properties in Japanese A 78-week treatment with ABL showed improvement in HSA parameters associated with hip geometry and biomechanical properties vs placebo. Archives of osteoporosis • 2023-11-30 • Phase III Randomized Trial | N = 128 | 88/100 | PMID 38030806 ↗ |
Abaloparatide Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.2700/unit (~$38.10/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $146.85 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 4 Anonymous DotMD Community Micro-Logs | $59.94 / mo | View logs ↓ |
Abaloparatide Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Abaloparatide RxNorm Concept ID | 1921075 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.2700 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $146.85 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $59.94 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 89.00% Worth It (4 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Abaloparatide Patient Community, Cohort Filters & Dosage Logs
Cross-verified Abaloparatide (parathyroid hormone-related peptide analog) monograph synthesizing RxNorm 1921075, openFDA FAERS signals, and $59.94–$146.85 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Abaloparatide community threads and patient logs by age, biological sex, dosage, and treatment duration.